Cart
sales@molnova.com
Elagolix sodium
CAS No. 832720-36-2
Elagolix sodium( NBI-56418 sodium )
Catalog No. M20990 CAS No. 832720-36-2
Elagolix sodium is a GnRH receptor (GnRHR) antagonist ( IC50 and Ki of 0.25 and 3.7 nM respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 46 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 140 | In Stock |
|
| 50MG | 222 | In Stock |
|
| 100MG | 352 | In Stock |
|
| 200MG | 520 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameElagolix sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionElagolix sodium is a GnRH receptor (GnRHR) antagonist ( IC50 and Ki of 0.25 and 3.7 nM respectively).
-
DescriptionElagolix sodium is a GnRH receptor (GnRHR) antagonist ( IC50 and Ki of 0.25 and 3.7 nM respectively).
-
In Vitro——
-
In Vivo——
-
SynonymsNBI-56418 sodium
-
PathwayOthers
-
TargetOther Targets
-
RecptorGNRHR
-
Research AreaCancer
-
IndicationUterine leiomyoma
Chemical Information
-
CAS Number832720-36-2
-
Formula Weight653.57
-
Molecular FormulaC32H29F5N3NaO5
-
Purity>98% (HPLC)
-
SolubilityDMSO:50 mg/mL (76.50 mM); H2O:50 mg/mL (76.50 mM)
-
SMILESCOc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)[O-])c3ccccc3)c2=O)c1F.[Na+]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Barra F Scala C Ferrero S2.Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.Drugs Today (Barc). 2019 Apr;55(4):237-246.
molnova catalog
related products
-
Damascenone
Damascenone is a norisoprenoid ketone mainly found in red wines. It occurs naturally in tomato and grapes.
-
Zoliflodacin (b)
Zoliflodacin?is a new antibiotic that inhibits DNA biosynthesis.
-
Eltoprazine dihydroc...
Eltoprazine dihydrochloride is a drug that had previously been developed for aggression has recently been investigated for L-DOPA-induced dyskinesia in animal models of Parkinson′s disease (PD) and in dyskinetic PD patients.?
